Positive Results in Cancer Vaccine Trial for Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Morphogenesis, Inc., a biotechnology company focused on developing cancer vaccines, in partnership with CohBar, believes they have met their milestone with IFx-HU2.0, a cancer vaccine studied in advanced Merkel cell carcinoma and squamous cell carcinoma.
Dmitry Rinberg on the Mysteries of Smell
“Don’t miss this fascinating interview with Dmitry Rinberg, Co-founder and Chief Science Advisor of Canaery, a resident of UF Innovate | Accelerate, as he explores the mysteries of smell with Vasant Dhar. Join AI-pioneer Vasant Dhar as he hosts ‘Brave New World’ and discover the transformation of humanity by machines in the post-COVID era. The conversation will touch on various topics such as work, health, faith, emotional well-being, government, democracy, and freedom.”
MLM Biologics Developing Wound Infection Prevention Device for Military
MLM Biologics Inc., a graduate company of Sid Martin Biotech, has been awarded nearly $1.5 million by the US Army to develop a device that prevents infection in battlefield wounds. The device will utilize MLM Biologic’s collagen processing and stabilization technologies. The focus is on preventing infection in complex, traumatic injuries in austere environments. The company plans to incorporate their proprietary technologies and proven anti-inflammatory and anti-microbial components, with potential civilian use in the future.
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
CohBar, Inc. and Morphogenesis, Inc., a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.
Entrinsic Bioscience Shares Breakthrough in Rehydration Technology
Groundbreaking research conducted by a team of leading researchers at Entrinsic Bioscience (EBS) and the University of Florida revealed significant findings that will change the way we understand amino acid combinations and represents the next generation of Oral Rehydration Solutions (ORS).
The Transformative Power of Tech Transfer: How One University Makes an Impact Around the Globe
UF Innovate has served as a model for universities nationwide looking to further their tech transfer efforts. UF connects innovators with entrepreneurs, investors and industry experts, while its business incubators (The Hub and Sid Martin Biotech) take research discoveries from the laboratory to the market. Since its inception in 1995, UF Innovate has generated more than $10.4 billion in private investments, launched upwards of 300 startups via tech licensing, and created 7,900-plus startup jobs.
Amend Surgical Unveils Tough Adhesive Hydrogel for Intraoral Adhesion and Drug Delivery
In a groundbreaking development, Amend Surgical has announced the first-ever publication on the use of its Amend Tissue Tape, also known as DenTAI, in an oral application. The company is thrilled to report that the results have exceeded expectations and validated the extensive research and development that has gone into this revolutionary product platform. This exciting news paves the way for Amend Surgical to bring its transformative product to the market next year.
Glint Pharmaceuticals Receives FDA IND Acceptance for Clinical Study for Phase 1/2 Clinical Trial of Antibiotic Drug-Releasing Contact Lens, ACL5
UF startup Glint Pharmaceuticals (Glint), a clinical-stage biotechnology company focused on developing a next-generation contact lens drug delivery technology, announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate its antibiotic drug delivery contact lens, ACL5. Glint anticipates beginning the investigation in Q2 2023.
Using Whole-Genome Sequencing To Study Early-Onset Parkinson’s Disease
The Norwegian term for virgin snow, “nysnø”, seemed the appropriate inspiration to name Jennifer Johnston’s company, NysnoBio, as it underscores the pioneering work NysnoBio is doing to tap the potential of Parkin, the protein most often linked to young onset genetic Parkinson’s disease.
A Founder’s Collaboration Skills May Be the Key to Success, Especially in Deep Tech
Accelerators like UF Innovate are crucial to the early-stage economy, and to innovation in the United States. It’s at places like these that new technologies can be brought to the market, including technologies that with a profound effect on people’s lives and health. One UF Innovate company, for instance, is MYOLYN, which makes therapy systems for people with neurological disorders and injuries, like multiple sclerosis or stroke.